JG
URGN icon

Jain Global’s UroGen Pharma URGN Stock Holding History

Jain Global’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Buy
+6,902
New +$187K ﹤0.01% 1453
2025
Q2 		– Sell
-13,291
Closed -$147K – 1628
2025
Q1 		$147K Buy
+13,291
New +$142K ﹤0.01% 917

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Jain Global's URGN Position: Q2 2026 in Review

Jain Global opened a new position in UroGen Pharma (URGN) in Q2 2026: 6,902 shares worth $254K. The stake represents ﹤0.01% of the portfolio and ranks #1453 among its holdings. This is a return to the name: Jain Global previously reported a position in URGN as recently as Q1 2025.

Jain Global first reported a position in URGN in Q1 2025 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Jain Global held 6,902 shares of UroGen Pharma worth $254K as of Q2 2026.
  • UroGen Pharma was a new Jain Global position in Q2 2026.
  • UroGen Pharma made up ﹤0.01% of Jain Global's portfolio in Q2 2026, its #1453 holding.
  • Jain Global first reported a position in UroGen Pharma in Q1 2025 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.